Table 2 Patients with reduced relative dose intensity (RDI) (percent of patients with reductions are presented)
| Â | Planned RDI <85% of standard (%) | Overall actual RDI <85% (%) | RDI <85% for 1+ cycle (%) | Planned RDI <90% of standard (%) | Overall actual RDI <90% (%) | RDI <90% for 1+ cycle (%) |
|---|---|---|---|---|---|---|
All (n = 1,176)a | 13.4 | 22.2 | 32.5 | 17.0 | 30.5 | 40.0 |
Age | ||||||
 <50 years (n = 443) | 12.4 | 16.0 | 26.0 | 15.3 | 23.5 | 33.2 |
 50–64 years (n = 537) | 12.5 | 23.1 | 34.3 | 16.0 | 32.2 | 40.8 |
 ≥65 years (n = 196) | 17.9 | 33.7 | 42.3 | 23.5 | 41.8 | 53.1 |
Menopausal statusa | ||||||
 Pre-menopausal (n = 479) | 10.4 | 14.4 | 23.4 | 12.9 | 21.7 | 30.3 |
 Post-menopausal (n = 690) | 15.2 | 27.4 | 38.6 | 19.7 | 36.4 | 46.4 |
ECOG performance status | ||||||
 0 (n = 917) | 12.5 | 20.9 | 31.2 | 15.8 | 28.8 | 37.7 |
 1 (n = 235) | 15.3 | 26.4 | 35.7 | 20.0 | 36.6 | 47.2 |
 2–4 (n = 24) | 25.0 | 29.2 | 50.0 | 33.3 | 37.5 | 54.2 |
Prior chemotherapy | ||||||
 No (n = 1,085) | 13.1 | 21.9 | 32.4 | 16.7 | 30.1 | 39.9 |
 Yes (n = 91) | 16.5 | 25.3 | 34.1 | 20.9 | 35.2 | 40.7 |
Baseline body surface area | ||||||
 ≤2 m2 (n = 908) | 10.7 | 19.9 | 30.3 | 13.9 | 28.2 | 38.0 |
 >2 m2 (n = 268) | 22.4 | 29.9 | 39.9 | 27.6 | 38.4 | 46.6 |
Body mass indexa | ||||||
 <30 kg/m2 (n = 750) | 9.5 | 17.9 | 28.1 | 12.5 | 25.6 | 35.3 |
 30 to  <35 kg/m2 (n = 220) | 16.8 | 30.0 | 38.6 | 20.0 | 36.8 | 45.0 |
 ≥35 kg/m2 (n = 203) | 23.6 | 29.6 | 41.9 | 30.0 | 41.9 | 51.7 |
Hormone receptorsa | ||||||
 ER+ or PR+ (n = 753) | 13.9 | 22.0 | 32.9 | 18.1 | 30.3 | 41.2 |
 ER− and PR− (n = 378) | 11.6 | 22.2 | 30.4 | 14.3 | 29.9 | 36.5 |